Published in J Clin Oncol on January 01, 1998
RALOX or CAPOX + Bevacizumab in the First-line Treatment of Advanced CRC(ROCB Study) | NCT03813641
Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy. J Clin Oncol (2009) 5.42
Less is more, regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice. J Clin Invest (2000) 3.26
Mismatch repair proficiency and in vitro response to 5-fluorouracil. Gastroenterology (1999) 3.06
Systemic treatment of colorectal cancer. Gastroenterology (2008) 2.62
MicroRNA-21 induces resistance to 5-fluorouracil by down-regulating human DNA MutS homolog 2 (hMSH2). Proc Natl Acad Sci U S A (2010) 1.99
Non-coding MicroRNAs hsa-let-7g and hsa-miR-181b are Associated with Chemoresponse to S-1 in Colon Cancer. Cancer Genomics Proteomics (2006) 1.94
Development history and concept of an oral anticancer agent S-1 (TS-1): its clinical usefulness and future vistas. Jpn J Clin Oncol (2008) 1.87
Management of advanced colorectal cancer: state of the art. Br J Cancer (2006) 1.62
Perfusion MRI for the prediction of treatment response after preoperative chemoradiotherapy in locally advanced rectal cancer. Eur Radiol (2012) 1.56
The clinical and economic benefits of capecitabine and tegafur with uracil in metastatic colorectal cancer. Br J Cancer (2006) 1.56
Chemotherapy for advanced colorectal cancer. BMJ (2000) 1.50
S-1 in gastric cancer: a comprehensive review. Gastric Cancer (2003) 1.41
5-Fluorouracil: forty-plus and still ticking. A review of its preclinical and clinical development. Invest New Drugs (2000) 1.40
Comparison of the pharmacokinetics of S-1, an oral anticancer agent, in Western and Japanese patients. J Pharmacokinet Pharmacodyn (2003) 1.28
EORTC Early Clinical Studies Group early phase II trial of S-1 in patients with advanced or metastatic colorectal cancer. Br J Cancer (2003) 1.25
Definitive chemoradiation in patients with inoperable oesophageal carcinoma. Br J Cancer (2004) 1.13
DNA mismatch repair proficiency executing 5-fluorouracil cytotoxicity in colorectal cancer cells. Cancer Biol Ther (2011) 1.11
Twelve weeks of protracted venous infusion of fluorouracil (5-FU) is as effective as 6 months of bolus 5-FU and folinic acid as adjuvant treatment in colorectal cancer. Br J Cancer (2003) 1.10
Adjuvant treatment for gastric cancer: chemotherapy versus radiation. Oncologist (2013) 1.06
Metastatic colorectal cancer-past, progress and future. World J Gastroenterol (2007) 1.04
Chemotherapeutic implications in microsatellite unstable colorectal cancer. Cancer Biomark (2006) 1.01
Personalized colon cancer care in 2010. Semin Oncol (2011) 1.01
Toxic effects and their management: daily clinical challenges in the treatment of colorectal cancer. Nat Rev Clin Oncol (2009) 1.00
Cost-effectiveness analysis of cetuximab/irinotecan vs active/best supportive care for the treatment of metastatic colorectal cancer patients who have failed previous chemotherapy treatment. Br J Cancer (2007) 0.99
Efficacy of hepatic arterial infusion chemotherapy in advanced hepatocellular carcinoma. World J Gastroenterol (2012) 0.95
Phase II study of capecitabine and mitomycin C as first-line treatment in patients with advanced colorectal cancer. Br J Cancer (2004) 0.95
5-fu metabolism in cancer and orally-administrable 5-fu drugs. Cancers (Basel) (2010) 0.95
TAS-102, a novel antitumor agent: A review of the mechanism of action. Cancer Treat Rev (2015) 0.94
Impact of neoadjuvant chemoradiation on pathologic response and survival of patients with locally advanced rectal cancer. Rep Pract Oncol Radiother (2010) 0.94
Deletion of p53 in human mammary epithelial cells causes chromosomal instability and altered therapeutic response. Oncogene (2010) 0.94
Management of stage IV rectal cancer: palliative options. World J Gastroenterol (2011) 0.93
Balancing the efficacy and toxicity of chemotherapy in colorectal cancer. Ther Adv Med Oncol (2011) 0.92
Tegafur-uracil is a safe alternative for the treatment of colorectal cancer in patients with partial dihydropyrimidine dehydrogenase deficiency: a proof of principle. Ther Adv Med Oncol (2012) 0.91
Phase II study of single agent capecitabine in the treatment of metastatic non-pancreatic neuroendocrine tumours. Br J Cancer (2011) 0.90
Phase II study of UFT and oxaliplatin in first-line treatment of advanced colorectal cancer. Br J Cancer (2004) 0.90
Conceptual changes in cancer chemotherapy: from an oral fluoropyrimidine prodrug, UFT, to a novel oral fluoropyrimidine prodrug, S-1, and low-dose FP therapy in Japan. Invest New Drugs (2000) 0.89
An individual patient data meta-analysis of adjuvant therapy with uracil-tegafur (UFT) in patients with curatively resected rectal cancer. Br J Cancer (2007) 0.89
Contributions of meta-analyses based on individual patient data to therapeutic progress in colorectal cancer. Int J Clin Oncol (2009) 0.88
Clinical efficacy of S-1 combined with cisplatin for advanced gastric cancer. Gastric Cancer (2003) 0.88
Capecitabine as a radiosensitizing agent in neoadjuvant treatment of locally advanced resectable rectal cancer: prospective phase II trial. Croat Med J (2006) 0.88
Altered deoxyuridine and thymidine in plasma following capecitabine treatment in colorectal cancer patients. Br J Clin Pharmacol (2006) 0.87
Phase II study of UFT with leucovorin and irinotecan (TEGAFIRI): first-line therapy for metastatic colorectal cancer. Br J Cancer (2007) 0.86
Laparoscopic extraperitoneal rectal cancer surgery: the clinical practice guidelines of the European Association for Endoscopic Surgery (EAES). Surg Endosc (2011) 0.86
Clinical activity of patupilone in patients with pretreated advanced/metastatic colon cancer: results of a phase I dose escalation trial. Br J Cancer (2011) 0.85
Efficacy of a continuous venous infusion of fluorouracil and daily divided dose cisplatin as adjuvant therapy in resectable colorectal cancer: a prospective randomized trial. Surg Today (2008) 0.85
Treatment of colorectal cancer using a combination of liposomal irinotecan (Irinophore C™) and 5-fluorouracil. PLoS One (2013) 0.85
Comparison of the efficacy of oral capecitabine versus bolus 5-FU in preoperative radiotherapy of locally advanced rectal cancer. J Korean Med Sci (2006) 0.85
Weekly irinotecan plus UFT and leucovorin as first-line chemotherapy of patients with advanced colorectal cancer. Invest New Drugs (2005) 0.85
Cyclin E and histone H3 levels are regulated by 5-fluorouracil in a DNA mismatch repair-dependent manner. Cancer Biol Ther (2010) 0.85
Adjuvant chemoradiation for gastric cancer with infusional 5-fluorouracil and cisplatin: a phase I study. Curr Oncol (2010) 0.84
A review of the pharmacology and clinical activity of new chemotherapy agents for the treatment of colorectal cancer. Br J Clin Pharmacol (1999) 0.84
Advances in the treatment of metastatic colorectal cancer. Am J Ther (2009) 0.84
Surrogacy assessment using principal stratification and a Gaussian copula model. Stat Methods Med Res (2014) 0.83
Comparison of the efficacy and safety of S-1-based and capecitabine-based regimens in gastrointestinal cancer: a meta-analysis. PLoS One (2014) 0.83
Prospective phase II study of preoperative chemoradiation with capecitabine in locally advanced rectal cancer. Cancer Res Treat (2004) 0.83
Tegafur/gimeracil/oteracil (S-1) approved for the treatment of advanced gastric cancer in adults when given in combination with cisplatin: a review comparing it with other fluoropyrimidine-based therapies. Onco Targets Ther (2011) 0.82
The tegafur-based dihydropyrimidine dehydrogenase inhibitory fluoropyrimidines, UFT/leucovorin (ORZEL) and S-1: a review of their clinical development and therapeutic potential. Invest New Drugs (2000) 0.82
Capecitabine with radiation is an effective adjuvant therapy in gastric cancers. World J Gastroenterol (2010) 0.82
Current targeted therapies in the treatment of advanced colorectal cancer: a review. Ther Adv Med Oncol (2016) 0.81
Surrogacy assessment using principal stratification with multivariate normal and Gaussian copula models. Clin Trials (2014) 0.81
Complete remission of unresectable colon cancer after preoperative chemotherapy selected by adenosine triphosphate-based chemotherapy response assay. J Korean Med Sci (2008) 0.81
A phase II study of UFT with leucovorin administered as a twice daily schedule in the treatment of patients with metastatic colorectal cancer. Br J Cancer (2008) 0.81
Analysis of the time course and prognostic factors determining toxicity due to infused fluorouracil. Br J Cancer (2003) 0.80
Evolvement of the treatment paradigm for metastatic colon cancer. From chemotherapy to targeted therapy. Crit Rev Oncol Hematol (2011) 0.80
A phase II study of irinotecan, 5-fluorouracil and leucovorin for treatment in patients with previously untreated advanced colorectal cancer. Cancer Res Treat (2006) 0.80
A phase I study of combination therapy with S-1 and irinotecan (CPT-11) in patients with advanced colorectal cancer. J Cancer Res Clin Oncol (2008) 0.80
Advances of Targeted Therapy in Treatment of Unresectable Metastatic Colorectal Cancer. Biomed Res Int (2016) 0.79
Long-term survival benefits of adjuvant chemotherapy by decreasing incidence of tumor recurrence without delaying relapse in stage III colorectal cancer. Int J Colorectal Dis (2011) 0.79
Acidic tumor microenvironment downregulates hMLH1 but does not diminish 5-fluorouracil chemosensitivity. Mutat Res (2013) 0.79
Capecitabine for locally advanced and metastatic colorectal cancer: A review. World J Gastrointest Oncol (2010) 0.79
Management of locally advanced and metastatic colon cancer in elderly patients. World J Gastroenterol (2014) 0.79
Current directions in chemotherapy for colorectal cancer. J Gastroenterol (2006) 0.79
Future directions in combined modality therapy for rectal cancer: reevaluating the role of total mesorectal excision after chemoradiotherapy. Onco Targets Ther (2013) 0.79
Effect of port-care frequency on venous port catheter-related complications in cancer patients. Int J Clin Oncol (2013) 0.78
The efficacy of a modified chronomodulated infusion of oxaliplatin, 5-fluorouracil and leucovorin in advanced colorectal cancer (preliminary data). Cancer Res Treat (2004) 0.78
Neoadjuvant oral vs. infusional chemoradiotherapy on locally advanced rectal cancer: Prognostic factors. Rep Pract Oncol Radiother (2012) 0.78
Impact of the new AJCC staging system and adjuvant treatment in rectal cancer. Cancer Res Treat (2004) 0.78
Phase I clinical and pharmacokinetic study of oxaliplatin, irinotecan and capecitabine. Cancer Chemother Pharmacol (2008) 0.78
Refining docetaxel-containing therapy for gastric cancer. Gastrointest Cancer Res (2011) 0.78
S-1 plus oxaliplatin versus capecitabine plus oxaliplatin for the first-line treatment of patients with metastatic colorectal cancer: updated results from a phase 3 trial. BMC Cancer (2014) 0.78
Emerging role of S-1 in gastric cancer. Indian J Med Paediatr Oncol (2016) 0.78
Preoperative concomitant radiotherapy with oral capecitabine in advanced rectal cancer within 6 cm from anal verge. Int J Colorectal Dis (2008) 0.78
Chemotherapy and other systemic therapies for hepatocellular carcinoma and liver metastases. Semin Intervent Radiol (2006) 0.78
Oxaliplatin: is it a new standard weapon for colorectal cancer? Cancer Res Treat (2004) 0.78
A phase II study of leucovorin, 5-FU and docetaxel combination chemotherapy in patients with inoperable or postoperative relapsed gastric cancer. Cancer Res Treat (2008) 0.78
Bi-weekly docetaxel and 5-fluorouracil: an effective and feasible treatment for advanced gastric cancer with poor performance status. Gastroenterol Rep (Oxf) (2014) 0.77
Patient considerations in metastatic colorectal cancer - role of panitumumab. Onco Targets Ther (2017) 0.77
A retrospective observational study on the safety and efficacy of first-line treatment with bevacizumab combined with FOLFIRI in metastatic colorectal cancer. Br J Cancer (2010) 0.77
Phase I dose-escalation trial of irinotecan with continuous infusion 5-FU first line, in metastatic colorectal cancer. Br J Cancer (2004) 0.77
Pharmacokinetic properties and antitumor efficacy of the 5-fluorouracil loaded PEG-hydrogel. BMC Cancer (2010) 0.77
A phase II study of intravenous exatecan mesylate (DX-8951f) administered daily for five days every three weeks to patients with metastatic adenocarcinoma of the colon or rectum. Invest New Drugs (2004) 0.76
Production of truncated MBD4 protein by frameshift mutation in DNA mismatch repair-deficient cells enhances 5-fluorouracil sensitivity that is independent of hMLH1 status. Cancer Biol Ther (2016) 0.76
Phase I trial of combined irinotecan and oxaliplatin given every three weeks to patients with metastatic colorectal cancer. Invest New Drugs (2004) 0.76
A phase I study of vitamin E, 5-fluorouracil and leucovorin for advanced malignancies. Invest New Drugs (2001) 0.76
Multicentre phase II study of leucovorin plus pharmacokinetic modulating chemotherapy for metastatic colorectal cancer. Oncol Lett (2010) 0.76
Effect of Neoadjuvant Chemoradiotherapy with Capecitabine versus Fluorouracil for Locally Advanced Rectal Cancer: A Meta-Analysis. Gastroenterol Res Pract (2016) 0.76
The role of chemotherapy in colon cancer. Ochsner J (2002) 0.75
Should capecitabine replace 5-fluorouracil in the first-line treatment of metastatic colorectal cancer? World J Gastroenterol (2014) 0.75
Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med (2001) 18.77
Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet (2000) 12.56
Interpreting the significance of changes in health-related quality-of-life scores. J Clin Oncol (1998) 9.89
The outcomes and costs of care for acute low back pain among patients seen by primary care practitioners, chiropractors, and orthopedic surgeons. The North Carolina Back Pain Project. N Engl J Med (1995) 6.95
Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results. J Natl Cancer Inst (2000) 5.62
Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study. J Clin Oncol (2001) 5.25
The effect of debulking surgery after induction chemotherapy on the prognosis in advanced epithelial ovarian cancer. Gynecological Cancer Cooperative Group of the European Organization for Research and Treatment of Cancer. N Engl J Med (1995) 4.75
The relative importance of T cell subsets in immunity and immunopathology of airborne Mycobacterium tuberculosis infection in mice. J Exp Med (2001) 4.50
Long-term results of lung metastasectomy: prognostic analyses based on 5206 cases. J Thorac Cardiovasc Surg (1997) 4.47
Radiotherapy alone versus combined chemotherapy and radiotherapy in nonresectable non-small-cell lung cancer: first analysis of a randomized trial in 353 patients. J Natl Cancer Inst (1991) 4.24
Clinical determinants of survival in patients with 5-fluorouracil-based treatment for metastatic colorectal cancer: results of a multivariate analysis of 3825 patients. Ann Oncol (2002) 3.91
Risk factors for the sexual transmission of genital herpes. Ann Intern Med (1992) 3.89
Recurrences after oral and genital herpes simplex virus infection. Influence of site of infection and viral type. N Engl J Med (1987) 3.42
A functional imaging study of cooperation in two-person reciprocal exchange. Proc Natl Acad Sci U S A (2001) 3.41
Association between air pollution and low birth weight: a community-based study. Environ Health Perspect (1997) 3.32
Risk of internal cancers from arsenic in drinking water. Environ Health Perspect (2000) 3.29
Relation between tumour response to first-line chemotherapy and survival in advanced colorectal cancer: a meta-analysis. Meta-Analysis Group in Cancer. Lancet (2000) 3.27
Hydrogen peroxide-producing lactobacilli and acquisition of vaginal infections. J Infect Dis (1996) 3.23
Neonatal herpes simplex virus infection in relation to asymptomatic maternal infection at the time of labor. N Engl J Med (1991) 3.19
The polymicrobial origin of intestinal infections in homosexual men. N Engl J Med (1983) 3.12
Concurrent chemotherapy-radiotherapy compared with radiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: progression-free survival analysis of a phase III randomized trial. J Clin Oncol (2002) 3.11
Center for Birth Defects Information Services. Birth Defects Orig Artic Ser (1980) 3.09
Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French intergroup study. J Clin Oncol (1997) 3.08
First-line oral capecitabine therapy in metastatic colorectal cancer: a favorable safety profile compared with intravenous 5-fluorouracil/leucovorin. Ann Oncol (2002) 2.87
Hepatic arterial infusion of floxuridine in patients with liver metastases from colorectal carcinoma: long-term results of a prospective randomized trial. J Clin Oncol (1992) 2.86
Are long-chain polyunsaturated fatty acids essential nutrients in infancy? Lancet (1995) 2.73
A double-blind study of oral acyclovir for suppression of recurrences of genital herpes simplex virus infection. N Engl J Med (1984) 2.71
Fraud in medical research: an international survey of biostatisticians. ISCB Subcommittee on Fraud. Control Clin Trials (2000) 2.67
Body mass index as a predictor of hepatic steatosis in living liver donors. Liver Transpl (2001) 2.66
Defective gamma interferon production in leprosy. Reversal with antigen and interleukin 2. J Exp Med (1983) 2.61
Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy: a prospective study of 626 patients with identification of risk factors. J Med Virol (2000) 2.58
The phosphotyrosine interaction domains of X11 and FE65 bind to distinct sites on the YENPTY motif of amyloid precursor protein. Mol Cell Biol (1996) 2.57
Skin thickness score in systemic sclerosis: an assessment of interobserver variability in 3 independent studies. J Rheumatol (1993) 2.56
Human toll-like receptor 2 mediates monocyte activation by Listeria monocytogenes, but not by group B streptococci or lipopolysaccharide. J Immunol (2000) 2.49
Localization of the X inactivation centre on the human X chromosome in Xq13. Nature (1991) 2.48
Leptin secretion and leptin receptor in the human stomach. Gut (2000) 2.46
Treatment of poorly differentiated neuroendocrine tumours with etoposide and cisplatin. Br J Cancer (1999) 2.40
Down syndrome and thyroid function in adults. Lancet (1975) 2.39
Individual Physician Profile: continuing education related to medical practice. J Med Educ (1973) 2.34
Overall mortality and cancer mortality around French nuclear sites. Nature (1990) 2.31
Patients' evaluation of shape, size and colour of solid dosage forms. Pharm World Sci (2001) 2.30
Insulin resistance syndrome in a representative sample of children and adolescents from Quebec, Canada. Int J Obes Relat Metab Disord (2004) 2.26
Provocation of bradycardia and hypotension by isoproterenol and upright posture in patients with unexplained syncope. N Engl J Med (1989) 2.26
Asymptomatic reactivation of herpes simplex virus in women after the first episode of genital herpes. Ann Intern Med (1992) 2.25
Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: an updated meta-analysis. J Clin Oncol (2004) 2.24
Effect of recombinant human granulocyte-macrophage colony-stimulating factor on chemotherapy-induced myelosuppression. N Engl J Med (1988) 2.23
Non-small-cell lung carcinoma tumor growth without morphological evidence of neo-angiogenesis. Am J Pathol (1997) 2.19
Quinolone-based antibacterial chemoprophylaxis in neutropenic patients: effect of augmented gram-positive activity on infectious morbidity. National Cancer Institute of Canada Clinical Trials Group. Ann Intern Med (1996) 2.15
Phase II study of oxaliplatin, fluorouracil, and folinic acid in locally advanced or metastatic gastric cancer patients. J Clin Oncol (2002) 2.15
Psychometric properties and responsiveness of the EORTC quality of Life Questionnaire (QLQ-C30) in patients with breast, ovarian and lung cancer. Qual Life Res (1994) 2.11
Survival analysis in natural history studies of disease. Stat Med (1989) 2.11
Toxicity of fluorouracil in patients with advanced colorectal cancer: effect of administration schedule and prognostic factors. J Clin Oncol (1998) 2.05
Quality of life is predictive of survival in patients with unresectable hepatocellular carcinoma. Ann Oncol (2006) 2.04
Development of clinically recognizable genital lesions among women previously identified as having "asymptomatic" herpes simplex virus type 2 infection. Ann Intern Med (1989) 2.03
Patterns of failure following loco-regional radiotherapy in the treatment of limited stage small cell lung cancer. Int J Radiat Oncol Biol Phys (1994) 2.01
Hydroxyurea for treatment of severe sickle cell anemia: a pediatric clinical trial. Blood (1996) 2.01
Extent of nicotine and cotinine transfer to the human fetus, placenta and amniotic fluid of smoking mothers. Dev Pharmacol Ther (1985) 1.98
Multiple trace theory of human memory: computational, neuroimaging, and neuropsychological results. Hippocampus (2000) 1.97
The prenatal detection of significant alcohol exposure with maternal blood markers. J Pediatr (1998) 1.96
A direct comparison of CellSearch and ISET for circulating tumour-cell detection in patients with metastatic carcinomas. Br J Cancer (2011) 1.95
Double-blind placebo-controlled trial of oral acyclovir in first-episode genital herpes simplex virus infection. JAMA (1984) 1.94
Oral capecitabine vs intravenous 5-fluorouracil and leucovorin: integrated efficacy data and novel analyses from two large, randomised, phase III trials. Br J Cancer (2004) 1.94
DNA damage in human sperm is related to urinary levels of phthalate monoester and oxidative metabolites. Hum Reprod (2006) 1.94
Combination of surgery and chemotherapy and the role of targeted agents in the treatment of patients with colorectal liver metastases: recommendations from an expert panel. Ann Oncol (2009) 1.93
Reappraisal of hepatic arterial infusion in the treatment of nonresectable liver metastases from colorectal cancer. J Natl Cancer Inst (1996) 1.93
Curative treatment of peritoneal carcinomatosis arising from colorectal cancer by complete resection and intraperitoneal chemotherapy. Cancer (2001) 1.92
ASTRO (American Society for Therapeutic Radiology and Oncology) plenary: Effect of chemotherapy on locally advanced non-small cell lung carcinoma: a randomized study of 353 patients. GETCB (Groupe d'Etude et Traitement des Cancers Bronchiques), FNCLCC (Féderation Nationale des Centres de Lutte contre le Cancer) and the CEBI trialists. Int J Radiat Oncol Biol Phys (1991) 1.91
Effects on infants of a first episode of genital herpes during pregnancy. N Engl J Med (1987) 1.91